Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 66,046	$ 193,198
Accounts receivable	103,914	193,094
Prepaid expenses and other assets	39,768	50,530
Income taxes refundable	35,399	35,399
Loan receivable from Emergence Global Enterprises Inc. - related party	0	0
Total current assets	245,127	472,221
Other assets
Operating lease right-of-use assets	111,853	138,103
Other receivable	5,338	0
Note receivable - CEN Biotech Ukraine LLC - related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC - related party	1,299,328	1,299,328
Property and equipment, net	77,399	97,403
Deferred income taxes	(2,720)	(2,720)
Intangible assets, net	(4,972,976)	(5,072,031)
Goodwill	1,314,134	1,314,134
Total assets	8,073,734	8,440,799
Current liabilities
Accounts payable	396,303	440,332
Accounts payable – related parties	75,561	101,422
Loans payable	1,688,793	1,688,793
Loans payable – related parties	2,701,641	2,701,641
Convertible notes payable, net of unamortized discount	713,330	643,330
Convertible notes payable, net of unamortized discount - related parties	162,639	162,639
Accrued interest	1,427,791	1,361,689
Accrued interest – related parties	1,977,812	1,873,455
Operating lease liabilities	115,709	103,908
Governmental assistance payable	145,333	145,333
Accrued expenses	322,158	638,073
Total current liabilities	9,727,070	9,860,615
Operating lease liabilities, less current portion	174,082	206,763
CEBA loan payable	31,552	31,552
Total liabilities	9,932,704	10,098,930
Commitments and contingencies (Notes 4, 11, 12, 18, 19, 24, and 25)
Shareholders’ deficit
Common stock; unlimited authorized shares; 61,804,729 and 55,957,743 issued and outstanding as of June 30, 2022, and December 31, 2021, respectively. No par value.	0	0
Additional paid-in capital	44,746,286	44,339,973
Accumulated deficit	(46,569,501)	(45,964,183)
Accumulated other comprehensive loss	(35,755)	(33,921)
Total shareholders’ deficit	(1,858,970)	(1,658,131)
Total liabilities and shareholders’ deficit	$ 8,073,734	$ 8,440,799